

Resource Summary Report

Generated by [RRID](#) on Sep 8, 2026

Anti-TIGIT antibody [BLR047F] - BSA free

RRID:AB_2943164

Type: Antibody

Proper Citation

Abcam Cat# ab243903, RRID:AB_2943164

Antibody Information

URL: http://antibodyregistry.org/AB_2943164

Proper Citation: Abcam Cat# ab243903, RRID:AB_2943164

Target Antigen: TIGIT

Host Organism: rabbit

Clonality: monoclonal

Antibody Name: Anti-TIGIT antibody [BLR047F] - BSA free

Description: This monoclonal targets TIGIT

Target Organism: human

Clone ID: BLR047F

Antibody ID: AB_2943164

Vendor: Abcam

Catalog Number: ab243903

Record Creation Time: 20231110T031123+0000

Record Last Update: 20260829T003132+0000

Ratings and Alerts

No rating or validation information has been found for Anti-TIGIT antibody [BLR047F] - BSA free.

No alerts have been found for Anti-TIGIT antibody [BLR047F] - BSA free.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Podaza E, et al. (2026) Tumor immune microenvironment reconstitution in patient-derived organoids enables therapy modeling for NSCLC. Cell reports methods, 6(6), 101339.

Shang X, et al. (2026) Dual PD-1/IL-2R γ targeting restores CD8⁺ T cell fitness via STAT5/CD47 axis in SMARCA4-deficient NSCLC. Cell reports. Medicine, 7(3), 102633.

Liu HM, et al. (2025) Neoadjuvant immunotherapy with or without chemotherapy in locally advanced oral squamous cell carcinoma: Randomized, two-arm, phase 2 trial. Cell reports. Medicine, 6(2), 101930.

Liu YT, et al. (2025) Immune-featured stromal niches associate with response to neoadjuvant immunotherapy in oral squamous cell carcinoma. Cell reports. Medicine, 6(3), 102024.

Zhu B, et al. (2025) Spatial and multiomics analysis of human and mouse lung adenocarcinoma precursors reveals TIM-3 as a putative target for precancer interception. Cancer cell, 43(6), 1125.

Guégan JP, et al. (2024) Analysis of PD1, LAG3, TIGIT, and TIM3 expression in human lung adenocarcinoma reveals a 25-gene signature predicting immunotherapy response. Cell reports. Medicine, 5(12), 101831.